Vasoactive Medications

LIDO Study: in a multicenter, randomised, double-blind, double-dummy, parallel-group trial. Levosimendan (a calcium sensitizer that improved contractility without an increase in oxygen demand) vs dobutamine for low-output heart failure was used. Mortality at 180 days, 26% vs 38%, ARR 12%, NNT 8.3, p = 0.029 (re: Follath F. Lancet 2002; 360: 196).